Clinical Trial Update: Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating faster-acting insulin aspart vs NovoRapid in combination with insulin degludec in children and adolescents with type 1 diabetes; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus in Children and Adolescents

Drugs mentioned

• Faster-acting insulin aspart (insulin aspart)
• NovoRapid (insulin aspart)
• insulin degludec (insulin degludec)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2019-04-04